Metastatic cancer stem cells: From the concept to therapeutics

American Journal of Stem Cells

Volumn 3, Issue 2, 2014, Pages 46-62

  Liao, Wen Ting ^a   Ye, Ya Ping ^a   Deng, Yong Jian ^a   Bian, Xiu Wu ^b   Ding, Yan Qing ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Cancer stem cells; Invasion and metastasis; Therapeutics

Indexed keywords

ABC TRANSPORTER; ALDEHYDE DEHYDROGENASE ISOENZYME 1; ARF PROTEIN; BIOLOGICAL MARKER; CD133 ANTIGEN; CD24 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; COLLAGENASE 3; DIPEPTIDYL PEPTIDASE IV; EPITHELIAL CELL ADHESION MOLECULE; GELATINASE A; GELATINASE B; HERMES ANTIGEN; NESTIN; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; PRION PROTEIN; PROTEIN P53; STROMAL CELL DERIVED FACTOR 1; TELOMERASE; THROMBOPOIETIN RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ACUTE GRANULOCYTIC LEUKEMIA; ANGIOGENESIS; CANCER INHIBITION; CANCER STEM CELL; CARCINOGENIC ACTIVITY; CELL DIFFERENTIATION; CELL INVASION; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; GENE LOCUS; GENE MUTATION; HUMAN; IMMUNOSURVEILLANCE; LYMPHANGIOGENESIS; METASTASIS; NONHUMAN; PLURIPOTENT STEM CELL; REVIEW; SIGNAL TRANSDUCTION; STEM CELL NICHE; TUMOR VASCULARIZATION;

EID: 84906922339     PISSN: None     EISSN: 21604150     Source Type: Journal    
DOI: None     Document Type: Review

References (170)

1. Nguyen DX, Bos PD and Massague J. Metasta-sis: from dissemination to organ-specific colonization. Nat Rev Cancer 2009; 9: 274-284.
2. Valastyan S and Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. Cell 2011; 147: 275-292.
3. Luzzi KJ, MacDonald IC, Schmidt EE, Kerkvliet N, Morris VL, Chambers AF and Groom AC. Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am J Patho 1998; 153: 865-873.
4. Reya T, Morrison SJ, Clarke MF and Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-111.
5. Li F, Tiede B, Massague J and Kang Y. Beyond tumorigenesis: cancer stem cells in metastasis. Cell Res 2007; 17: 3-14.
6. Dreesen O and Brivanlou AH. Signaling pathways in cancer and embryonic stem cells. Stem Cell Rev 2007; 3: 7-17.
7. Baumann M, Krause M and Hill R. Exploring the role of cancer stem cells in radioresistance. Nat Rev Cancer 2008; 8: 545-554.
8. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, Visvader J, Weissman IL and Wahl GM. Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 2006; 66: 9339-9344.
9. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, Minden M, Paterson B, Caligiuri MA and Dick JE. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994; 367: 645-648.
10. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ and Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003; 100: 3983-3988.
11. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD and Dirks PB. Identification of human brain tumour initiating cells. Nature 2004; 432: 396-401.
12. O’Brien CA, Pollett A, Gallinger S and Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007; 445: 106-110.
13. Huynh CK, Brodie AM and Njar VC. Inhibitory effects of retinoic acid metabolism blocking agents (RAMBAs) on the growth of human prostate cancer cells and LNCaP prostate tu-mour xenografts in SCID mice. Br J Cancer 2006; 94: 513-523.
14. Collins AT, Berry PA, Hyde C, Stower MJ and Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005; 65: 10946-10951.
15. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF and Simeone DM. Identification of pancreatic cancer stem cells. Cancer Res 2007; 67: 1030-1037.
16. Dalerba P, Cho RW and Clarke MF. Cancer stem cells: models and concepts. Annu Rev Med 2007; 58: 267-284.
17. Medema JP. Cancer stem cells: The challenges ahead. Nat Cell Biol 2013; 15: 338-344.
18. Stower H. Telomeres: stem cells, cancer and telomerase linked by WNT. Nat Rev Genet 2012; 13: 521.
19. Moserle L, Ghisi M, Amadori A and Indraccolo S. Side population and cancer stem cells: therapeutic implications. Cancer Lett 2010; 288: 1-9.
20. Baccelli I and Trumpp A. The evolving concept of cancer and metastasis stem cells. J Cell Biol 2012; 198: 281-293.
21. Alison MR, Lim SM and Nicholson LJ. Cancer stem cells: problems for therapy? J Pathol 2011; 223: 147-161.
22. Wilson A, Laurenti E, Oser G, van der Wath RC, Blanco-Bose W, Jaworski M, Offner S, Dunant CF, Eshkind L, Bockamp E, Lio P, Macdonald HR and Trumpp A. Hematopoietic stem cells reversibly switch from dormancy to self-renewal during homeostasis and repair. Cell 2008; 135: 1118-1129.
23. Essers MA, Offner S, Blanco-Bose WE, Waibler Z, Kalinke U, Duchosal MA and Trumpp A. IF-Nalpha activates dormant haematopoietic stem cells in vivo. Nature 2009; 458: 904-908.
24. Fuchs E. The tortoise and the hair: slow-cycling cells in the stem cell race. Cell 2009; 137: 811-819.
25. Ishii H, Iwatsuki M, Ieta K, Ohta D, Haraguchi N, Mimori K and Mori M. Cancer stem cells and chemoradiation resistance. Cancer Sci 2008; 99: 1871-1877.
26. Tehranchi R, Woll PS, Anderson K, Buza-Vidas N, Mizukami T, Mead AJ, Astrand-Grundstrom I, Strombeck B, Horvat A, Ferry H, Dhanda RS, Hast R, Ryden T, Vyas P, Gohring G, Schlegel-berger B, Johansson B, Hellstrom-Lindberg E, List A, Nilsson L and Jacobsen SE. Persistent malignant stem cells in del (5q) myelodysplasia in remission. N Engl J Med 2010; 363: 1025-1037.
27. Bjerkvig R, Johansson M, Miletic H and Niclou SP. Cancer stem cells and angiogenesis. Se-min Cancer Biol 2009; 19: 279-284.
28. Ribatti D. Cancer stem cells and tumor angiogenesis. Cancer Lett 2012; 321: 13-17.
29. Ping YF, Yao XH, Jiang JY, Zhao LT, Yu SC, Jiang T, Lin MC, Chen JH, Wang B, Zhang R, Cui YH, Qian C, Wang J and Bian XW. The chemokine CXCL12 and its receptor CXCR4 promote glioma stem cell-mediated VEGF production and tumour angiogenesis via PI3K/AKT signalling. J Pathol 2011; 224: 344-354.
30. Ye XZ, Yu SC and Bian XW. Contribution of myeloid-derived suppressor cells to tumor-induced immune suppression, angiogenesis, invasion and metastasis. J Genet Genomics 2010; 37: 423-430.
31. Yao XH, Ping YF and Bian XW. Contribution of cancer stem cells to tumor vasculogenic mimicry. Protein Cell 2011; 2: 266-272.
32. De Maria R, Grignani F, Testa U, Valtieri M, Ziegler BL and Peschle C. Gene regulation in normal and leukaemic progenitor/stem cells. Haematologica 1999; 84 Suppl EHA-4:8-10.
33. Bonnet D and Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3: 730-737.
34. Wang Y, Yang J, Zheng H, Tomasek GJ, Zhang P, McKeever PE, Lee EY and Zhu Y. Expression of mutant p53 proteins implicates a lineage relationship between neural stem cells and malignant astrocytic glioma in a murine model. CanCer Cell 2009; 15: 514-526.
35. Li H, Collado M, Villasante A, Strati K, Ortega S, Canamero M, Blasco MA and Serrano M. The Ink4/Arf locus is a barrier for iPS cell reprogramming. Nature 2009; 460: 1136-1139.
36. Utikal J, Polo JM, Stadtfeld M, Maherali N, Kulalert W, Walsh RM, Khalil A, Rheinwald JG and Hochedlinger K. Immortalization eliminates a roadblock during cellular reprogramming into iPS cells. Nature 2009; 460: 1145-1148.
37. Kawamura T, Suzuki J, Wang YV, Menendez S, Morera LB, Raya A, Wahl GM and Izpisua Bel-monte JC. Linking the p53 tumour suppressor pathway to somatic cell reprogramming. Nature 2009; 460: 1140-1144.
38. Takahashi K and Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors Cell 2006; 126: 663-676.
39. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K and Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131: 861-872.
40. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Nie J, Jonsdottir GA, Ruotti V, Stewart R, Slukvin II, Thomson JA. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007; 318: 1917-1920.
41. Okita K, Ichisaka T and Yamanaka S. Generation of germline-competent induced pluripotent stem cells. Nature 2007; 448: 313-317.
42. Kim JB, Zaehres H, Wu G, Gentile L, Ko K, Sebastiano V, Arauzo-Bravo MJ, Ruau D, Han DW, Zenke M and Scholer HR. Pluripotent stem cells induced from adult neural stem cells by reprogramming with two factors. Nature 2008; 454: 646-650.
43. Aoi T, Yae K, Nakagawa M, Ichisaka T, Okita K, Takahashi K, Chiba T and Yamanaka S. Generation of pluripotent stem cells from adult mouse liver and stomach cells. Science 2008; 321: 699-702.
44. Liang Y, Zhong Z, Huang Y, Deng W, Cao J, Tsao G, Liu Q, Pei D, Kang T and Zeng YX. Stem-like cancer cells are inducible by increasing genomic instability in cancer cells. J Biol Chem 2010; 285: 4931-4940.
45. Yang MH, Hsu DS, Wang HW, Wang HJ, Lan HY, Yang WH, Huang CH, Kao SY, Tzeng CH, Tai SK, Chang SY, Lee OK and Wu KJ. Bmi1 is essential in Twist1-induced epithelial-mesenchymal transition. Nat Cell Biol 2010; 12: 982-992.
46. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J and Weinberg RA. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133: 704-715.
47. Tang DG. Understanding cancer stem cell heterogeneity and plasticity. Cell Res 2012; 22: 457-472.
48. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, Schott A, Hayes D, Birnbaum D, Wicha MS and Dontu G. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical out-come. Cell Stem Cell 2007; 1: 555-567.
49. Pece S, Tosoni D, Confalonieri S, Mazzarol G, Vecchi M, Ronzoni S, Bernard L, Viale G, Pelicci PG and Di Fiore PP. Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell 2010; 140: 62-73.
50. Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, Gobel U, Goodell MA and Brenner MK. A distinct “side population” of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci U S A 2004; 101: 14228-14233.
51. Hope KJ, Jin L and Dick JE. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat Immunol 2004; 5: 738-743.
52. Shipitsin M, Campbell LL, Argani P, Weremow-icz S, Bloushtain-Qimron N, Yao J, Nikolskaya T, Serebryiskaya T, Beroukhim R, Hu M, Halushka MK, Sukumar S, Parker LM, Anderson KS, Harris LN, Garber JE, Richardson AL, Schnitt SJ, Nikolsky Y, Gelman RS and Polyak K. Molecular definition of breast tumor heterogeneity. Cancer Cell 2007; 11: 259-273.
53. Park SY, Gonen M, Kim HJ, Michor F and Polyak K. Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype. J Clin Invest 2010; 120: 636-644.
54. Lottaz C, Beier D, Meyer K, Kumar P, Hermann A, Schwarz J, Junker M, Oefner PJ, Bogdahn U, Wischhusen J, Spang R, Storch A and Beier CP. Transcriptional profiles of CD133+ and CD133-glioblastoma-derived cancer stem cell lines suggest different cells of origin. Cancer Res 2010; 70: 2030-2040.
55. Horwitz EM. Stem cell plasticity: the growing potential of cellular therapy. Arch Med Res 2003; 34: 600-606.
56. Martin-Rendon E and Watt SM. Stem cell plasticity. Br J Haematol 2003; 122: 877-891.
57. Orlic D, Kajstura J, Chimenti S, Jakoniuk I, Anderson SM, Li B, Pickel J, McKay R, Nadal-Ginard B, Bodine DM, Leri A and Anversa P. Bone marrow cells regenerate infarcted myocardium. Nature 2001; 410: 701-705.
58. Orlic D, Kajstura J, Chimenti S, Limana F, Jakoniuk I, Quaini F, Nadal-Ginard B, Bodine DM, Leri A and Anversa P. Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc Natl Acad Sci U S A 2001; 98: 10344-10349.
59. Jackson KA, Majka SM, Wang H, Pocius J, Hart-ley CJ, Majesky MW, Entman ML, Michael LH, Hirschi KK and Goodell MA. Regeneration of ischemic cardiac muscle and vascular endothelium by adult stem cells. J Clin Invest 2001; 107: 1395-1402.
60. Ferrari G, Cusella-De Angelis G, Coletta M, Paolucci E, Stornaiuolo A, Cossu G and Mavilio F. Muscle regeneration by bone marrow-derived myogenic progenitors. Science 1998; 279: 1528-1530.
61. Terskikh AV, Easterday MC, Li L, Hood L, Korn-blum HI, Geschwind DH and Weissman IL. From hematopoiesis to neuropoiesis: evidence of overlapping genetic programs. Proc Natl Acad Sci U S A 2001; 98: 7934-7939.
62. Hendrix MJ, Seftor EA, Hess AR and Seftor RE. Molecular plasticity of human melanoma cells. Oncogene 2003; 22: 3070-3075.
63. Casal C, Torres-Collado AX, Plaza-Calonge Mdel C, Martino-Echarri E, Ramon YCS, Rojo F, Griffioen AW and Rodriguez-Manzaneque JC. ADAMTS1 contributes to the acquisition of an endothelial-like phenotype in plastic tumor cells. Cancer Res 2010; 70: 4676-4686.
64. Wang R, Chadalavada K, Wilshire J, Kowalik U, Hovinga KE, Geber A, Fligelman B, Leversha M, Brennan C and Tabar V. Glioblastoma stem-like cells give rise to tumour endothelium. Nature 2010; 468: 829-833.
65. Ricci-Vitiani L, Pallini R, Biffoni M, Todaro M, Invernici G, Cenci T, Maira G, Parati EA, Stassi G, Larocca LM and De Maria R. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 2010; 468: 824-828.
66. Valastyan S and Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. Cell 2011; 147: 275-292.
67. Cameron MD, Schmidt EE, Kerkvliet N, Nad-karni KV, Morris VL, Groom AC, Chambers AF and MacDonald IC. Temporal progression of metastasis in lung: cell survival, dormancy, and location dependence of metastatic ineffi-ciency. Cancer Res 2000; 60: 2541-2546.
68. Hynes RO. Metastatic potential: generic predisposition of the primary tumor or rare, metastatic variants-or both? Cell 2003; 113: 821-823.
69. Bernards R and Weinberg RA. A progression puzzle. Nature 2002; 418: 823.
70. Thiery JP, Acloque H, Huang RY and Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009; 139: 871-890.
71. Cano A, Perez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, del Barrio MG, Portillo F and Nieto MA. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2000; 2: 76-83.
72. Bolos V, Peinado H, Perez-Moreno MA, Fraga MF, Esteller M and Cano A. The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transi-tions: a comparison with Snail and E47 repres-sors. J Cell Sci 2003; 116: 499-511.
73. Eger A, Aigner K, Sonderegger S, Dampier B, Oehler S, Schreiber M, Berx G, Cano A, Beug H and Foisner R. DeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells. Oncogene 2005; 24: 2375-2385.
74. Liu Y, El-Naggar S, Darling DS, Higashi Y and Dean DC. Zeb1 links epithelial-mesenchymal transition and cellular senescence. Development 2008; 135: 579-588.
75. Song LB, Li J, Liao WT, Feng Y, Yu CP, Hu LJ, Kong QL, Xu LH, Zhang X, Liu WL, Li MZ, Zhang L, Kang TB, Fu LW, Huang WL, Xia YF, Tsao SW, Li M, Band V, Band H, Shi QH, Zeng YX and Zeng MS. The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cells. J Clin Invest 2009; 119: 3626-3636.
76. Yilmaz M and Christofori G. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev 2009; 28: 15-33.
77. Vermeulen L, De Sousa EMF, van der Heijden M, Cameron K, de Jong JH, Borovski T, Tuynman JB, Todaro M, Merz C, Rodermond H, Sprick MR, Kemper K, Richel DJ, Stassi G and Medema JP. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol 2010; 12: 468-476.
78. Moustakas A and Heldin CH. Signaling net-works guiding epithelial-mesenchymal transitions during embryogenesis and cancer progression. Cancer Sci 2007; 98: 1512-1520.
79. Polyak K and Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 2009; 9: 265-273.
80. Acloque H, Adams MS, Fishwick K, Bronner-Fraser M and Nieto MA. Epithelial-mesenchymal transitions: the importance of changing cell state in development and disease. J Clin Invest 2009; 119: 1438-1449.
81. Shimono Y, Zabala M, Cho RW, Lobo N, Dalerba P, Qian D, Diehn M, Liu H, Panula SP, Chiao E, Dirbas FM, Somlo G, Pera RA, Lao K and Clarke MF. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell 2009; 138: 592-603.
82. Wellner U, Schubert J, Burk UC, Schmalhofer O, Zhu F, Sonntag A, Waldvogel B, Vannier C, Darling D, zur Hausen A, Brunton VG, Morton J, Sansom O, Schuler J, Stemmler MP, Herzberger C, Hopt U, Keck T, Brabletz S and Brabletz T. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol 2009; 11: 1487-1495.
83. Battula VL, Evans KW, Hollier BG, Shi Y, Marini FC, Ayyanan A, Wang RY, Brisken C, Guerra R, Andreeff M and Mani SA. Epithelial-mesenchymal transition-derived cells exhibit multilineage differentiation potential similar to mesenchymal stem cells. Stem Cells 2010; 28: 1435-1445.
84. Asiedu MK, Ingle JN, Behrens MD, Radisky DC and Knutson KL. TGFbeta/TNF(alpha)-mediated epithelial-mesenchymal transition generates breast cancer stem cells with a claudin-low phenotype. Cancer Res 2011; 71: 4707-4719.
85. Yang L, Ping YF, Yu X, Qian F, Guo ZJ, Qian C, Cui YH and Bian XW. Gastric cancer stem-like cells possess higher capability of invasion and metastasis in association with a mesenchymal transition phenotype. Cancer Lett 2011; 310: 46-52.
86. Zlobec I and Lugli A. Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: tumor budding as oncotarget. Oncotarget 2010; 1: 651-661.
87. Markl B and Arnholdt HM. Prognostic significance of tumor budding in gastrointestinal tumors. Expert Rev Anticancer Ther 2011; 11: 1521-1533.
88. Brabletz T, Jung A, Reu S, Porzner M, Hlubek F, Kunz-Schughart LA, Knuechel R and Kirchner T. Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc Natl Acad Sci U S A 2001; 98: 10356-10361.
89. Tsai JH, Donaher JL, Murphy DA, Chau S and Yang J. Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. Cancer Cell 2012; 22: 725-736.
90. Husemann Y, Geigl JB, Schubert F, Musiani P, Meyer M, Burghart E, Forni G, Eils R, Fehm T, Riethmuller G and Klein CA. Systemic spread is an early step in breast cancer. Cancer Cell 2008; 13: 58-68.
91. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Al-lard WJ, Terstappen LW and Hayes DF. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004; 351: 781-791.
92. Fehm T, Braun S, Muller V, Janni W, Gebauer G, Marth C, Schindlbeck C, Wallwiener D, Borgen E, Naume B, Pantel K and Solomayer E. A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation. Cancer 2006; 107: 885-892.
93. Baccelli I, Schneeweiss A, Riethdorf S, Stenzinger A, Schillert A, Vogel V, Klein C, Saini M, Bauerle T, Wallwiener M, Holland-Letz T, Hofner T, Sprick M, Scharpff M, Marme F, Sinn HP, Pantel K, Weichert W and Trumpp A. Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol 2013; 31: 539-544.
94. Maheswaran S and Haber DA. Circulating tumor cells: a window into cancer biology and metastasis. Curr Opin Genet Dev 2010; 20: 96-99.
95. Balic M, Lin H, Young L, Hawes D, Giuliano A, McNamara G, Datar RH and Cote RJ. Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin Cancer Res 2006; 12: 5615-5621.
96. Theodoropoulos PA, Polioudaki H, Agelaki S, Kallergi G, Saridaki Z, Mavroudis D and Georgoulias V. Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer. Cancer Lett 2010; 288: 99-106.
97. Sun YF, Xu Y, Yang XR, Guo W, Zhang X, Qiu SJ, Shi RY, Hu B, Zhou J and Fan J. Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection. Hepatology 2013; 57: 1458-1468.
98. Tinhofer I, Saki M, Niehr F, Keilholz U and Bu-ach V. Cancer stem cell characteristics of circulating tumor cells. Int J Radiat Biol 2014; 90: 622-7.
99. Yang ZF, Ngai P, Ho DW, Yu WC, Ng MN, Lau CK, Li ML, Tam KH, Lam CT, Poon RT and Fan ST. Identification of local and circulating cancer stem cells in human liver cancer. Hepatology 2008; 47: 919-928.
100. Kasimir-Bauer S, Hoffmann O, Wallwiener D, Kimmig R and Fehm T. Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells. Breast Cancer Res 2012; 14: R15.
101. Aktas B, Tewes M, Fehm T, Hauch S, Kimmig R and Kasimir-Bauer S. Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast CanCer Res 2009; 11: R46.
102. Ma J, Lin JY, Alloo A, Wilson BJ, Schatton T, Zhan Q, Murphy GF, Waaga-Gasser AM, Gasser M, Stephen Hodi F, Frank NY and Frank MH. Isolation of tumorigenic circulating melanoma cells. Biochem Biophys Res Commun 2010; 402: 711-717.
103. Paget S. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev 1989; 8: 98-101.
104. Fidler IJ. The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer 2003; 3: 453-458.
105. Polyak K and Hahn WC. Roots and stems: stem cells in cancer. Nat Med 2006; 12: 296-300.
106. Wicha MS. Cancer stem cells and metastasis: lethal seeds. Clin Cancer Res 2006; 12: 5606-5607.
107. Todaro M, Gaggianesi M, Catalano V, Benfante A, Iovino F, Biffoni M, Apuzzo T, Sperduti I, Volpe S, Cocorullo G, Gulotta G, Dieli F, De Maria R and Stassi G. CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis. Cell Stem Cell 2014; 14: 342-356.
108. Liu H, Patel MR, Prescher JA, Patsialou A, Qian D, Lin J, Wen S, Chang YF, Bachmann MH, Shimono Y, Dalerba P, Adorno M, Lobo N, Bueno J, Dirbas FM, Goswami S, Somlo G, Condeelis J, Contag CH, Gambhir SS and Clarke MF. Cancer stem cells from human breast tumors are involved in spontaneous metastases in orthotopic mouse models. Proc Natl Acad Sci U S A 2010; 107: 18115-18120.
109. Smith MC, Luker KE, Garbow JR, Prior JL, Jackson E, Piwnica-Worms D and Luker GD. CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res 2004; 64: 8604-8612.
110. Su L, Zhang J, Xu H, Wang Y, Chu Y, Liu R and Xiong S. Differential expression of CXCR4 is associated with the metastatic potential of human non-small cell lung cancer cells. Clin CanCer Res 2005; 11: 8273-8280.
111. Zlotnik A. New insights on the role of CXCR4 in cancer metastasis. J Pathol 2008; 215: 211-213.
112. Saur D, Seidler B, Schneider G, Algul H, Beck R, Senekowitsch-Schmidtke R, Schwaiger M and Schmid RM. CXCR4 expression increases liver and lung metastasis in a mouse model of pancreatic cancer. Gastroenterology 2005; 129: 1237-1250.
113. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, Bruns CJ and Heeschen C. Distinct populations of cancer stem cells de-termine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007; 1: 313-323.
114. Conley SJ, Gheordunescu E, Kakarala P, Newman B, Korkaya H, Heath AN, Clouthier SG and Wicha MS. Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc Natl Acad Sci U S A 2012; 109: 2784-2789.
115. Keith B and Simon MC. Hypoxia-inducible factors, stem cells, and cancer. Cell 2007; 129: 465-472.
116. Bao S, Wu Q, Sathornsumetee S, Hao Y, Li Z, Hjelmeland AB, Shi Q, McLendon RE, Bigner DD and Rich JN. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 2006; 66: 7843-7848.
117. Folkins C, Shaked Y, Man S, Tang T, Lee CR, Zhu Z, Hoffman RM and Kerbel RS. Glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and stromal-derived factor 1. Cancer Res 2009; 69: 7243-7251.
118. Yao XH, Ping YF, Chen JH, Xu CP, Chen DL, Zhang R, Wang JM and Bian XW. Glioblastoma stem cells produce vascular endothelial growth factor by activation of a G-protein coupled formylpeptide receptor FPR. J Pathol 2008; 215: 369-376.
119. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, MacDonald DD, Jin DK, Shido K, Kerns SA, Zhu Z, Hicklin D, Wu Y, Port JL, Altorki N, Port ER, Ruggero D, Shmelkov SV, Jensen KK, Rafii S and Lyden D. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005; 438: 820-827.
120. Sceneay J, Smyth MJ and Moller A. The pre-metastatic niche: finding common ground. Cancer Metastasis Rev 2013; 32: 449-464.
121. Kaplan RN, Psaila B and Lyden D. Bone marrow cells in the ‘pre-metastatic niche’: within bone and beyond. Cancer Metastasis Rev 2006; 25: 521-529.
122. Psaila B and Lyden D. The metastatic niche: adapting the foreign soil. Nat Rev Cancer 2009; 9: 285-293.
123. Erler JT, Bennewith KL, Cox TR, Lang G, Bird D, Koong A, Le QT and Giaccia AJ. Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the pre-metastatic niche. Cancer Cell 2009; 15: 35-44.
124. Semenza GL. Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci 2012; 33: 207-214.
125. Malanchi I, Santamaria-Martinez A, Susanto E, Peng H, Lehr HA, Delaloye JF and Huelsken J. Interactions between cancer stem cells and their niche govern metastatic colonization. Nature 2012; 481: 85-89.
126. Lu X and Kang Y. Hypoxia and hypoxia-inducible factors: master regulators of metastasis. Clin Cancer Res 2010; 16: 5928-5935.
127. Wang Y, Liu Y, Malek SN, Zheng P and Liu Y. Targeting HIF1alpha eliminates cancer stem cells in hematological malignancies. Cell Stem Cell 2011; 8: 399-411.
128. Yang MH, Wu MZ, Chiou SH, Chen PM, Chang SY, Liu CJ, Teng SC and Wu KJ. Direct regulation of TWIST by HIF-1alpha promotes metastasis. Nat Cell Biol 2008; 10: 295-305.
129. Fazilaty H, Gardaneh M, Bahrami T, Salmaninejad A and Behnam B. Crosstalk between breast cancer stem cells and metastatic niche: emerging molecular metastasis pathway? Tumour Biol 2013; 34: 2019-2030.
130. Massague J. TGFbeta signalling in context. Nat Rev Mol Cell Biol 2012; 13: 616-630.
131. Brabletz T, Jung A, Spaderna S, Hlubek F and Kirchner T. Opinion: migrating cancer stem cells an integrated concept of malignant tumour progression. Nat Rev Cancer 2005; 5: 744-749.
132. Dieter SM, Ball CR, Hoffmann CM, Nowrouzi A, Herbst F, Zavidij O, Abel U, Arens A, Weichert W, Brand K, Koch M, Weitz J, Schmidt M, von Kalle C and Glimm H. Distinct types of tumor-initiating cells form human colon cancer tumors and metastases. Cell Stem Cell 2011; 9: 357-365.
133. Pang R, Law WL, Chu AC, Poon JT, Lam CS, Chow AK, Ng L, Cheung LW, Lan XR, Lan HY, Tan VP, Yau TC, Poon RT and Wong BC. A subpopulation of CD26+ cancer stem cells with metastatic capacity in human colorectal CanCer. Cell Stem Cell 2010; 6: 603-615.
134. Patel SA, Dave MA, Murthy RG, Helmy KY and Rameshwar P. Metastatic breast cancer cells in the bone marrow microenvironment: novel insights into oncoprotection. Oncol Rev 2011; 5: 93-102.
135. Sun S and Wang Z. ALDH high adenoid cystic carcinoma cells display cancer stem cell properties and are responsible for mediating metastasis. Biochem Biophys Res Commun 2010; 396: 843-848.
136. Ocana OH, Corcoles R, Fabra A, Moreno-Bueno G, Acloque H, Vega S, Barrallo-Gimeno A, Cano A and Nieto MA. Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prrx1. Cancer Cell 2012; 22: 709-724.
137. Moriyama T, Ohuchida K, Mizumoto K, Cui L, Ikenaga N, Sato N and Tanaka M. Enhanced cell migration and invasion of CD133+ pancreatic cancer cells cocultured with pancreatic stromal cells. Cancer 2010; 116: 3357-3368.
138. Bailey JM, Alsina J, Rasheed ZA, McAllister FM, Fu YY, Plentz R, Zhang H, Pasricha PJ, Bardeesy N, Matsui W, Maitra A and Leach SD. DCLK1 marks a morphologically distinct subpopulation of cells with stem cell properties in preinvasive pancreatic cancer. Gastroenterology 2014; 146: 245-256.
139. Zhang SS, Han ZP, Jing YY, Tao SF, Li TJ, Wang H, Wang Y, Li R, Yang Y, Zhao X, Xu XD, Yu ED, Rui YC, Liu HJ, Zhang L and Wei LX. CD133 (+) CXCR4 (+) colon cancer cells exhibit metastatic potential and predict poor prognosis of patients. BMC Med 2012; 10: 85.
140. Gao W, Chen L, Ma Z, Du Z, Zhao Z, Hu Z and Li Q. Isolation and phenotypic characterization of colorectal cancer stem cells with organ-specific metastatic potential. Gastroenterology 2013; 145: 636-646, e635.
141. Du L, Rao G, Wang H, Li B, Tian W, Cui J, He L, Laffin B, Tian X, Hao C, Liu H, Sun X, Zhu Y, Tang DG, Mehrpour M, Lu Y and Chen Q. CD44-positive cancer stem cells expressing cellular prion protein contribute to metastatic capacity in colorectal cancer. Cancer Res 2013; 73: 2682-2694.
142. Deng YJ, Tang N, Liu C, Zhang JY, An S, Peng YL, Ma LL, Li GQ, Jiang Q, Hu CT, Wang YN, Liang YZ, Bian XW, Fang W and Ding Y. CLIC4, ERp29 and Smac/DIABLO derived from metastatic cancer stem-like cells stratifies prognostic risks of colorectal cancer. Clin Cancer Res 2014; 20: 3809-17.
143. Bartucci M, Dattilo R, Moriconi C, Pagliuca A, Mottolese M, Federici G, Benedetto AD, Todaro M, Stassi G, Sperati F, Amabile MI, Pilozzi E, Patrizii M, Biffoni M, Maugeri-Sacca M, Piccolo S and De Maria R. TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells. Oncogene 2014; [Epub ahead of print].
144. Chen D, Bhat-Nakshatri P, Goswami C, Badve S and Nakshatri H. ANTXR1, a stem cell-enriched functional biomarker, connects collagen signaling to cancer stem-like cells and metastasis in breast cancer. Cancer Res 2013; 73: 5821-5833.
145. Wei W, Hu H, Tan H, Chow LW, Yip AY and Loo WT. Relationship of CD44+CD24-/low breast cancer stem cells and axillary lymph node metastasis. J Transl Med 2012; 10 Suppl 1: 6.
146. Krohn A, Song YH, Muehlberg F, Droll L, Beckmann C and Alt E. CXCR4 receptor positive spheroid forming cells are responsible for tumor invasion in vitro. Cancer Lett 2009; 280: 65-71.
147. Pilati P, Mocellin S, Bertazza L, Galdi F, Briarava M, Mammano E, Tessari E, Zavagno G and Nitti D. Prognostic value of putative circulating cancer stem cells in patients undergoing hepatic resection for colorectal liver metastasis. Ann Surg Oncol 2012; 19: 402-408.
148. Li C, Wu JJ, Hynes M, Dosch J, Sarkar B, Welling TH, Pasca di Magliano M and Simeone DM. c-Met is a marker of pancreatic cancer stem cells and therapeutic target. Gastroenterology 2011; 141: 2218-2227, e5.
149. Sun S and Wang Z. Head neck squamous cell carcinoma c-Met(+) cells display cancer stem cell properties and are responsible for cisplatin-resistance and metastasis. Int J Cancer 2011; 129: 2337-2348.
150. Adhikari AS, Agarwal N, Wood BM, Porretta C, Ruiz B, Pochampally RR and Iwakuma T. CD117 and Stro-1 identify osteosarcoma tumor-initiating cells associated with metastasis and drug resistance. Cancer Res 2010; 70: 4602-4612.
151. Inoue A, Takahashi H, Harada H, Kohno S, Ohue S, Kobayashi K, Yano H, Tanaka J and Ohnishi T. Cancer stem-like cells of glioblastoma characteristically express MMP-13 and display highly invasive activity Int J Oncol 2010; 37: 1121-1131.
152. Nian WQ, Chen FL, Ao XJ and Chen ZT. CXCR4 positive cells from Lewis lung carcinoma cell line have cancer metastatic stem cell characteristics. Mol Cell Biochem 2011; 355: 241-248.
153. Pantel K, Brakenhoff RH and Brandt B. Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer 2008; 8: 329-340.
154. Pantel K and Alix-Panabieres C. The clinical significance of circulating tumor cells. Nat Clin Pract Oncol 2007; 4: 62-63.
155. Wu Y and Wu PY. CD133 as a marker for CanCer stem cells: progresses and concerns. Stem Cells Dev 2009; 18: 1127-1134.
156. Grosse-Gehling P, Fargeas CA, Dittfeld C, Garbe Y, Alison MR, Corbeil D and Kunz-Schughart LA. CD133 as a biomarker for putative cancer stem cells in solid tumours: limitations, problems and challenges. J Pathol 2013; 229: 355-378.
157. Ma S, Lee TK, Zheng BJ, Chan KW and Guan XY. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene 2008; 27: 1749-1758.
158. Piao LS, Hur W, Kim TK, Hong SW, Kim SW, Choi JE, Sung PS, Song MJ, Lee BC, Hwang D and Yoon SK. CD133+ liver cancer stem cells modulate radioresistance in human hepatocellular carcinoma. Cancer Lett 2012; 315: 129-137.
159. Rappa G, Fodstad O and Lorico A. The stem cell-associated antigen CD133 (Prominin-1) is a molecular therapeutic target for metastatic melanoma. Stem Cells 2008; 26: 3008-3017.
160. Draffin JE, McFarlane S, Hill A, Johnston PG and Waugh DJ. CD44 potentiates the adherence of metastatic prostate and breast cancer cells to bone marrow endothelial cells. Cancer Res 2004; 64: 5702-5711.
161. Riechelmann H, Sauter A, Golze W, Hanft G, Schroen C, Hoermann K, Erhardt T and Gronau S. Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma. Oral Oncol 2008; 44: 823-829.
162. Piotrowicz RS, Damaj BB, Hachicha M, Incardona F, Howell SB and Finlayson M. A6 peptide activates CD44 adhesive activity, induces FAK and MEK phosphorylation, and inhibits the migration and metastasis of CD44-expressing cells. Mol Cancer Ther 2011; 10: 2072-2082.
163. Lee TK, Cheung VC and Ng IO. Liver tumorinitiating cells as a therapeutic target for hepatocellular carcinoma. Cancer Lett 2013; 338: 101-109.
164. Takebe N, Harris PJ, Warren RQ and Ivy SP. Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol 2011; 8: 97-106.
165. McGowan PM, Simedrea C, Ribot EJ, Foster PJ, Palmieri D, Steeg PS, Allan AL and Chambers AF. Notch1 inhibition alters the CD44hi/CD-24lo population and reduces the formation of brain metastases from breast cancer. Mol CanCer Res 2011; 9: 834-844.
166. Feldmann G, Fendrich V, McGovern K, Bedja D, Bisht S, Alvarez H, Koorstra JB, Habbe N, Kari-kari C, Mullendore M, Gabrielson KL, Sharma R, Matsui W and Maitra A. An orally bioavailable small-molecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer. Mol Cancer Ther 2008; 7: 2725-2735.
167. Ye J, Wu D, Wu P, Chen Z and Huang J. The cancer stem cell niche: cross talk between cancer stem cells and their microenvironment. Tumour Biol 2014; 35: 3945-3951.
168. Yi SY, Hao YB, Nan KJ and Fan TL. Cancer stem cells niche: A target for novel cancer therapeutics. Cancer Treat Rev 2013; 39: 290-296.
169. Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, Mino M, Cohen KS, Scadden DT, Hartford AC, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Chen HX, Shellito PC, Lauwers GY and Jain RK. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004; 10: 145-147.
170. Hill R., Marie-Egyptienne DT and Hedley DW. Cancer stem cells, hypoxia and metastasis. Se-min Radiat Oncol 2009; 19: 106-111.